ÂÜÀòÂÒÂ×

Matthew Szot serves as the Chief Financial Officer at Cadrenal Therapeutics, Inc. since May 2022, where the focus is on developing tecarfarin for anticoagulation therapy. In addition, Matthew Szot holds prominent positions as a member of the Board of Directors and Chairman of Audit and Compensation Committees at INVO Bioscience, Inc. and Vice Chairman of the Board of Directors at SenesTech Inc., where oversight includes management of audit functions. Previous experience includes serving as Chief Financial Officer at S&W Seed Company and Cardiff Partners, as well as having held financial roles at Eastside Distilling, Inc. and Rip Curl. Matthew Szot began a career in audit at KPMG LLP and holds a Bachelor of Science in Agricultural Economics and Accountancy from the University of Illinois Urbana-Champaign.